Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Imugene ( (AU:IMU) ) has shared an announcement.
Imugene Limited has applied to the ASX for quotation of 12,508,898 new ordinary fully paid shares, with an issue date of 30 April 2026. The securities form part of a transaction previously notified to the market, signalling a modest expansion of the company’s issued capital base that may support ongoing development activities and operational funding.
The new share quotation, while not large relative to typical market capitalisations in the biotechnology sector, incrementally increases Imugene’s tradable equity and could provide additional liquidity for investors. This move fits within the company’s ongoing capital management practices as it advances its immunotherapy pipeline, though the announcement itself does not detail any specific project or strategic initiative linked to the issuance.
The most recent analyst rating on (AU:IMU) stock is a Buy with a A$0.82 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
More about Imugene
Imugene Limited is an Australian-listed biotechnology company focused on developing and commercialising immunotherapies, primarily in the oncology space. The company targets cancer treatment markets through novel biologic and viral-based therapies aimed at enhancing the body’s immune response against tumours.
Average Trading Volume: 1,547,501
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$44.65M
Find detailed analytics on IMU stock on TipRanks’ Stock Analysis page.